Innoviva
INVA Small CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Innoviva en bref
Innoviva (INVA) is currently trading at 18,18 € with a market capitalization of 1,3 Md €. The trailing P/E ratio stands at 3.35x, with a forward P/E of 9.49x. The 52-week range spans from 14,32 € to 21,81 €; the current price is 16.6% below the yearly high. Year-over-year revenue growth stands at +10.6%. The net profit margin stands at 119.88%.
💰 Dividende
Innoviva currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
4 analystes évaluent Innoviva (INVA) au consensus : None. L'objectif de cours moyen est de 30,78 €, soit un potentiel de +69.29% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,61 € à 39,88 €.
Innoviva : la thèse d'investissement en détail
Innoviva (INVA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 10.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 74.1%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 50.72% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
Le scénario baissier
Short interest sits at 12.81% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.31, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 6.58x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
À surveiller
- The analyst consensus price target implies 69.29% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 119.88%
- Rentabilité élevée des capitaux propres (50.72% ROE)
- Marge brute élevée de 74.1% — signe d'un pouvoir de fixation des prix
- Actuellement jugée sous-évaluée
- Bilan solide avec faible endettement (D/E 24.7)
- Free cash flow positif
- –Positions vendeuses élevées (12.81%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (12.81%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Innoviva?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news